Loading
This review of chemotherapy in salivary gland cancers concluded that responses are uncommon and short, that observation is reasonable for slowly progressing disease, and that trials of targeted agents based on tumour biology were needed.
Systematic review of systemic therapy studies in recurrent or metastatic salivary gland carcinoma, summarising response rates to single agents and combinations by histology, the natural history of indolent adenoid cystic carcinoma, and early experience with targeted agents.
The observation-first approach for indolent metastases and the move to biomarker-directed therapy (HER2, androgen receptor, NTRK) on the salivary cancer pages follow this review's conclusions.
Shares Adenoid cystic carcinoma, Journal of Clinical Oncology.
Shares Salivary duct carcinoma, Journal of Clinical Oncology.
Shares Mucoepidermoid carcinoma, Adenoid cystic carcinoma, Salivary duct carcinoma.